T1	Participants 178 224	patients with locally advanced noninflammatory
T2	Participants 225 238	breast cancer
T3	Participants 427 513	patients with locally advanced breast cancer treated with chemotherapy and mastectomy.
T4	Participants 559 625	200 patients with clinical Stage III noninflammatory breast cancer
T5	Participants 723 789	179 patients treated with mastectomy after neoadjuvant chemotherap
T6	Participants 792 933	108 participated in a randomized component of the trial that compared a dose-escalated, hyperfractionated (twice-daily, b.i.d.) chest wall RT
